Description
ARA-290 — Cibinetide
ARA-290, also known as cibinetide, is an experimental peptide derived from part of the structure of erythropoietin (EPO). It was designed to investigate EPO’s potential tissue-protective and anti-inflammatory properties without stimulating red-blood-cell production in the way conventional EPO does.
Research has focused particularly on neuropathic pain and small-fibre nerve damage. Early human studies have investigated cibinetide in conditions involving small-fibre neuropathy, including sarcoidosis and diabetes, with researchers examining changes in pain, nerve function and nerve-fibre regeneration.
🧬 Areas of research include: neuropathic pain • small-fibre nerve function • nerve regeneration • inflammatory signalling • tissue protection • sensory function • cellular repair pathways.
One particularly interesting aspect of ARA-290 is its interaction with the innate repair receptor (IRR), which is associated with tissue-protective and inflammation-resolving pathways. This is quite different from peptides such as BPC-157 and TB-500, despite all three sometimes being marketed online under the broad banner of “recovery peptides.”
The evidence still needs to be kept in perspective. ARA-290/cibinetide remains experimental and is not an approved treatment in the UK. It shouldn’t be described as proven to repair nerve damage, cure neuropathy or eliminate chronic pain; the human research is promising but still limited.
Research use only — not intended for human consumption.
Reviews
There are no reviews yet.